Clinical studies of p53 in treatment and benefit of breast cancer patients.

1999 ◽  
pp. 51-59 ◽  
Author(s):  
J Bergh

This article describes p53 as a prognostic and predictive factor, together with some information on how best to determine the p53 status. By December 1998, 13,000 articles on p53 were identified on Pub Med, the National Library of Medicine. Within one week a further 62 articles were recorded making it difficult to give the complete p53 story. This review article will focus on discussing p53 in relation to its predictive potential. So far, no firm conclusions can be made based on the articles studied. This may be, in part, because many studies have used less than optimal techniques for determination of the p53 status, together with the fact that the studies lacked power to detect a potential difference in outcome from specific therapy in relation to p53 status.

Heliyon ◽  
2021 ◽  
pp. e07558
Author(s):  
Yahdiana Harahap ◽  
Athalia Theda Tanujaya ◽  
Farhan Nurahman ◽  
Aurelia Maria Vianney ◽  
Denni Joko Purwanto

2006 ◽  
Vol 17 (3) ◽  
pp. 424-428 ◽  
Author(s):  
L. Mercatali ◽  
V. Valenti ◽  
D. Calistri ◽  
S. Calpona ◽  
G. Rosti ◽  
...  

2020 ◽  
Vol 32 ◽  
pp. 108-114 ◽  
Author(s):  
José Luis Fougo ◽  
Isabel Amendoeira ◽  
Maria José Brito ◽  
Ana Paula Correia ◽  
Ana Gonçalves ◽  
...  

Mutagenesis ◽  
2012 ◽  
Vol 28 (1) ◽  
pp. 39-48 ◽  
Author(s):  
E. Uriol ◽  
M. Sierra ◽  
M. A. Comendador ◽  
J. Fra ◽  
P. Martínez-Camblor ◽  
...  

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
In Hee Lee ◽  
Soo Jung Lee ◽  
Jeeyeon Lee ◽  
Jin Hyang Jung ◽  
Ho Yong Park ◽  
...  

Abstract Background Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is a predictor of improved outcomes in breast cancer. In patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative breast cancer, the response to NAC is variable and mostly limited. This study was an investigation of the predictive relevance of parameters of 18F-FDG PET/CT for the pCR to NAC in patients with HR-positive, HER2–negative breast cancer. Methods: AH total of 109 consecutive HR-positive and HER2-negative breast cancer patients who were treated with NAC were enrolled in this prospective cohort study. The relationships between pretreatment 18F-FDG PET/CT and clinical outcomes including pathologic response to NAC were evaluated. Results: All patients finished their planned NAC cycles and eight patients (7.3%) achieved pCR. In the receiver operating characteristic (ROC) curve analysis, pSUVmax exhibited high sensitivity and specificity for predicting pCR. Furthermore, multivariate logistic regression analysis revealed pSUVmax as a predictive factor for pCR (hazard ratio = 17.452; 95% CI = 1.847–164.892; p = 0.013). Conclusion The results of this study suggest that 18F-FDG PET/CT pSUVmax is a predictive factor for pCR of HR-positive, HER2-negative breast cancer to NAC.


Sign in / Sign up

Export Citation Format

Share Document